Skip to main navigation Skip to search Skip to main content

A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of Durvalumab following stereotactic body radiation therapy (SBRT) for the treatment of Patients with Stage I/II Non Small Cell Lung Cancer

Upstate Medical University

Project: Research

Project Details

StatusFinished
Effective start/end date08/1/19 → 07/31/22

Funding

  • AstraZeneca Pharmaceuticals LP: $34,260.00